Century Therapeutics Q2 net loss misses estimates on lease termination loss

Century Therapeutics

12/08/2026 13:09

Overview
U.S. cell therapy developer's Q2 net loss widened yr/yr, missing analyst expectations
Q2 operating income missed analyst expectations
Company ended Q2 with $197.2 mln in cash and investments, runway into Q1 2029

Outlook
Century expects to submit IND for CNTY-813 in 4Q 2026, with initial clinical data in 2H 2027
Company anticipates CNTY-308 to enter the clinic in 2026
Century estimates cash runway into 1Q 2029

Result Drivers
R&D AND FACILITY COST REDUCTIONS - Co said lower Q2 R&D and G&A expenses were primarily due to reduced personnel and facility costs after portfolio prioritization
LEASE TERMINATION LOSS - Co recorded $11.1 mln loss on lease component termination in Q2

Company press release: ID:nGNX6LWr4C

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$34.55 mln
$22.38 mln (5 Analysts)
Q2 Operating Income
Miss
-$36.53 mln
-$24.48 mln (5 Analysts)
Q2 Loss Per Basic Share
 
$0.17
 
Q2 Operating Expenses
 
$36.53 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Century Therapeutics, Inc. is $5.00, about 142.7% above its August 11 closing price of $2.06

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Aug 10 - Sana Biotechnology Q2 adjusted loss narrows, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)